Ocugen

Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness and developing vaccines to save lives from COVID-19. Our breakthrough modified gene therapy platform has the potential to treat multiple retinal diseases with a single drug, and our novel biologic product candidates aim to provide better treatment for edema, wet age-related macular degeneration, diabetic macular edema, and other underserved diseases such as diabetic retinopathy. We are co-developing Bharat Biotech's COVID-19 vaccine candidate, COVAXIN, for the U.S. and Canadian markets.